Disease · MONDO_0015796

acute lung injury

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. acute lung injury. Diseases, record MONDO_0015796. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015796

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: acute lung injury; Open Targets
Open Targets ID: MONDO_0015796; Open Targets
Other names: ALI; Open Targets
MeSH: D055371; MeSH
NCI Thesaurus: C155766; NCI Thesaurus
Orphanet: ORPHA:178320; Orphanet
Highest stage of its drugs: Approval, for 4 of its 63 drugs, from TTD; Open Targets

Drugs63

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CALFACTANT	CHEMBL1201447		Approval	TTD	3	2	2	Drugs and targets
IVACAFTOR	CHEMBL2010601	Small molecule	Approval	TTD	2	0	0	Drugs and targets
LUMACAFTOR	CHEMBL2103870	Small molecule	Approval	TTD	1	0	0	Drugs and targets
TEZACAFTOR	CHEMBL3544914	Small molecule	Approval	TTD	1	0	0	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ROSUVASTATIN	CHEMBL1496	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ALBUMIN HUMAN	CHEMBL1201451	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
HETASTARCH	CHEMBL2108448		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
RAVULIZUMAB	CHEMBL3989986	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
L-CITRULLINE	CHEMBL444814	Small molecule	Phase 3	TTD	1	0	0	Drugs and targets

1 to 10 of 63

See all 63 drugs

Targets71

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA1A	Adrenergic receptor	4	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist	Phase 2	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor	4	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist	Phase 2	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor	4	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist	Phase 2	https://conductscience.org/library/genes/146	Drugs and targets
ADRB2	Adrenergic receptor	4	Adrenergic receptor agonist; Beta-2 adrenergic receptor agonist	Phase 2/3	https://conductscience.org/library/genes/154	Drugs and targets
ADRA2A	Adrenergic receptor	3	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist	Phase 2	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	3	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist	Phase 2	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor	3	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist	Phase 2	https://conductscience.org/library/genes/152	Drugs and targets
ADRB1	Adrenergic receptor	3	Adrenergic receptor agonist; Beta-1 adrenergic receptor agonist	Phase 2	https://conductscience.org/library/genes/153	Drugs and targets
C5	Complement C5	3	Complement C5 inhibitor	Phase 3	https://conductscience.org/library/genes/727	Drugs and targets
CFTR	Cystic fibrosis transmembrane conductance regulator	3	Cystic fibrosis transmembrane conductance regulator activator; Cystic fibrosis transmembrane conductance regulator positive modulator; Cystic fibrosis transmembrane conductance regulator stabiliser	Approval	https://conductscience.org/library/genes/1080	Drugs and targets

1 to 10 of 71

See all 71 targets

Trials46

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00979121	Statins for Acutely Injured Lungs From Sepsis	Phase 3	745	2014-10-03	Sepsis, Acute Lung Injury	ROSUVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT00434993	Drug Study of Albuterol to Treat Acute Lung Injury	Phase 2/3	282	2013-07-15	Respiratory Distress Syndrome, Adult	ALBUTEROL SULFATE	Its record names the disease	ClinicalTrials.gov
NCT04402866	TD-0903 for ALI Associated With COVID-19	Phase 2	235	2022-03-17	Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19	NEZULCITINIB	Its record names the disease	ClinicalTrials.gov
NCT04369469	Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia	Phase 3	202	2022-05-24	COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral	RAVULIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02106975	Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury	Phase 2	170	2019-10-15	Acute Lung Injury, Sepsis	ASCORBIC ACID	Its record names the disease	ClinicalTrials.gov
NCT04382924	Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease	Phase 2/3	168	2021-12-03	COVID	IFENPRODIL	Its record names the disease	ClinicalTrials.gov
NCT00201409	A Randomized Trial of GM-CSF in Patients With ALI/ARDS	Phase 2	132	2015-04-27	Respiratory Distress Syndrome, Adult	REGRAMOSTIM	Its record names the disease	ClinicalTrials.gov
NCT00351533	A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)	Phase 2	90	2011-10-03	Respiratory Distress Syndrome, Adult, Acute Lung Injury, Acute Respiratory Distress Syndrome	DOCONEXENT, ICOSAPENT	Its record names the disease	ClinicalTrials.gov
NCT04382755	Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure	Phase 2	81	2023-09-14	COVID-19	CEFTRIAXONE, CIPROFLOXACIN, ZILUCOPLAN	Its record names the disease	ClinicalTrials.gov
NCT00996840	SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS	Phase 2	77	2017-10-18	Lung Injury, Acute	DILMAPIMOD	Its record names the disease	ClinicalTrials.gov

1 to 10 of 46

See all 46 trials

Comparisons in its trials29

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Rosuvastatin vs Placebo: serious adverse events	34 of 379	32 of 366	745	NCT00979121	Trial comparisons
Albuterol Sulfate vs Placebo: serious adverse events	1 of 152	1 of 130	282	NCT00434993	Trial comparisons
Part 2: TD-0903 - 3 mg vs Part 2: Matching Placebo: Part 2: Number of Participants Alive and Respiratory Failure-free on Day 28	92 of 106	85 of 104	210	NCT04402866	Trial comparisons
Group 1 - Ravulizumab + BSC vs Group 2 - BSC Alone: deaths from any cause	55 of 135	25 of 66	201	NCT04369469	Trial comparisons
Group 1 - Ravulizumab + BSC vs Group 2 - BSC Alone: serious adverse events	79 of 127	38 of 67	194	NCT04369469	Trial comparisons
Ascorbic Acid vs 5% Dextrose in Water: deaths from any cause	25 of 84	38 of 83	167	NCT02106975	Trial comparisons
Ascorbic Acid vs 5% Dextrose in Water: serious adverse events	0 of 84	0 of 83	167	NCT02106975	Trial comparisons
GM-CSF Group vs Placebo Group: serious adverse events	31 of 64	34 of 66	130	NCT00201409	Trial comparisons
Enteral Fish Oil vs Enteral Saline: serious adverse events	12 of 41	10 of 49	90	NCT00351533	Trial comparisons
Enteral Fish Oil vs Enteral Saline: Hospital Mortality	9 of 41	10 of 48	89	NCT00351533	Trial comparisons

1 to 10 of 29

See all 29 comparisons in its trials

Papers from its trials45

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33826106	RESULT	1	PubMed
32660611	RESULT	1	PubMed
24503265	RESULT	1	PubMed
21399490	RESULT	1	PubMed
19417610	RESULT	1	PubMed
17621602	RESULT	1	PubMed
17426195	RESULT	1	PubMed
42536986	DERIVED	1	PubMed
37460276	DERIVED	1	PubMed
36958364	DERIVED	1	PubMed

1 to 10 of 45

See all 45 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0015796

GET https://conductscience.org/api/diseases/v1/MONDO_0015796/drugs?page=2

API reference For AI assistants